Association of Cyclooxygenase 2 Single-Nucleotide Polymorphisms and Hepatocellular Carcinoma in Taiwan

Wen-Shin Chang ； Mei-Due Yang ； Chia-Wen Tsai ； Li-Hao Cheng ； Long-Bin Jeng ； Woei-Chung Lo ； Chih-Hsueh Lin ； Chih-Yang Huang ； Da-Tian Bau

《The Chinese Journal of Physiology》 55卷1期 (2012/02) Pp. 1-7

https://doi.org/10.4077/CJP.2012.AMM056

並列摘要

Hepatocellular carcinoma (HCC) is a worldwide neoplasm for which early diagnosis is difficult and the prognosis is usually poor. Overexpression of cyclooxygenase 2 (COX-2) has been suggested to be associated with hepatocarcinogenesis. Although several COX-2 inhibitors have been used in hepatoma therapy, the genetic background between COX-2 and HCC remains largely unknown. In this study, the association of genotypic polymorphisms in COX-2 with HCC was investigated. 298 patients with HCC and 298 healthy controls recruited from the China Medical Hospital in Taiwan were genotyped by a PCR-RFLP method. We have investigated six polymorphic variants of COX-2, including A-1195G, G-765C, T+8473C, and variants in introns 1, 5 and 6, and analyzed the association of specific genotype(s) with susceptibility to HCC. The results showed that, for each of the six genotypes, no differences on distribution between the HCC and control groups were found. There was neither obvious joint effect of COX-2 G-765C/intron 6 haplotype nor its genotypes with smoking or alcohol consumption on HCC risk. Environmental factors, other than smoking and alcohol drinking, may affect the post-natal expression of COX-2 in the etiology of HCC, which is an outcome of complex genetic and environmental interactions. Moreover, our immunohistochemistrical results indicated that the COX-2 protein was significantly over-expressed in well-differentiated HCC, but not significantly increased in expression in poorly-differentiated HCC. We suggest that COX-2 may be a determinant of the differentiation grade of HCC.

並列關鍵字

COX-2 ； polymorphism ； hepatocellular carcinoma

參考文獻

Avila, M.A.,Berasain, C.,Sangro, B.,Prieto, J.(2006).New therapies for hepatocellular carcinoma.Oncogene.25,3866-3884.

Bae, S.H.,Jung, E.S.,Park, Y.M.,Kim, B.S.,Kim, B.K.,Kim, D.G.,Ryu, W.S.(2001).Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma, and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.Clin. Cancer Res..7,1410-1418.

Casado, M.,Callejas, N.A.,Rodrigo, J.,Zhao, X.,Dey, S.K.,Bosca, L.,Martin-Sanz, P.(2001).Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy.FASEB J..15,2016-2018.

Casado, M.,Molla, B.,Roy, R.,Fernandez-Martinez, A.,Cucarella, C.,Mayoral, R.,Bosca, L.,Martin-Sanz, P.(2007).Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes.Hepatology.45,631-638.

Chang, C.H.,Chang, C.L.,Tsai, C.W.,Wu, H.C.,Chiu, C.F.,Wang, R.F.,Liu, C.S.,Lin, C.C.,Bau, D.T.(2009).Significant association of an XRCC4 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan.Anticancer Res..29,1777-1782.